21.20.Z - Manufacture of medicines and other pharmaceutical products
10.98.Z - Manufacture of food products
20.42.Z - Manufacture of perfumes and toilet preparations
20.59.Z - Manufacture of other chemical products not elsewhere classified
32.50.Z - Manufacture of medical and dental instruments and supplies
46.45.Z - Wholesale of perfume and cosmetics
46.46.Z - Wholesale of pharmaceutical goods
70.22.Z - Business and other management consultancy activities
72.11.Z - Research and experimental development on biotechnology
72.19.Z - Other research and experimental development on natural sciences and engineering
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -1,3 | 2,9 | 10,3 | 257,2 |
EBITDA | 2,9 | 7,3 | 15,9 | 118,6 |
Short time liabilities | 39,4 | 23,5 | 32,3 | 37,4 |
Equity capital | 80,3 | 83,4 | 92,2 | 10,5 |
Operating profit (EBIT) | -0,9 | 3,5 | 10,9 | 211,7 |
Assets | 140,8 | 124,8 | 139,6 | 11,9 |
Net profit (loss) | -2,5 | 3,1 | 8,8 | 178,7 |
Cash | 0,3 | 0,1 | 0,2 | 262,1 |
Liabilities and provisions for liabilities | 60,5 | 41,4 | 47,4 | 14,6 |
Net income from sale | 75,5 | 80,5 | 80,8 | 0,4 |
Working assets | 58 | 33,5 | 45,5 | 35,9 |
Depreciation | 3,8 | 3,8 | 5,1 | 33,1 |
% | % | % | p.p. | |
Profitability of capital | -3,2 | 3,8 | 9,5 | 5,7 |
Equity capital to total assets | 57 | 66,8 | 66 | -0,8 |
Gross profit margin | -1,7 | 3,6 | 12,7 | 9,1 |
EBITDA Margin | 3,8 | 9,1 | 19,7 | 10,6 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 190 | 107 | 146 | 39 |
Current financial liquidity indicator | 1.4734572172164917 | 1.4223121404647827 | 1.4062265157699585 | 0 |
Net dept to EBITDA | 11.114224433898926 | 2.360670328140259 | 1.2102235555648804 | -1,2 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane